Comparative Pharmacology
Head-to-head clinical analysis: GABAPENTIN ENCARBIL versus PARADIONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GABAPENTIN ENCARBIL versus PARADIONE.
GABAPENTIN ENCARBIL vs PARADIONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gabapentin encarbil is a prodrug of gabapentin, which binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing calcium influx and inhibiting neurotransmitter release.
Paradione (paramethadione) is an oxazolidinedione anticonvulsant that suppresses neuronal activity in the motor cortex by increasing the threshold for repetitive neuronal firing and reducing synaptic transmission. Its exact mechanism is unclear but involves modulation of T-type calcium channels and enhancement of GABAergic inhibition.
Oral gabapentin encarbil 600 mg once daily with evening meal, titrated based on response and tolerability, maximum 1200 mg once daily. Alternatively, 600 mg twice daily may be used; maximum 2400 mg/day.
100 mg orally three times daily; maximum 600 mg/day.
None Documented
None Documented
The terminal elimination half-life of gabapentin derived from gabapentin encarbil is approximately 5-7 hours in patients with normal renal function. This half-life is prolonged in patients with renal impairment (up to 132 hours in anuria). Clinically, steady-state concentrations are achieved within 1-2 days. Twice-daily dosing is effective due to sustained exposure from the prodrug formulation.
12-24 hours (terminal); prolonged in renal impairment
Renal: Gabapentin encarbil is a prodrug of gabapentin. Following absorption, it is rapidly hydrolyzed to gabapentin. Gabapentin is primarily excreted unchanged in urine via glomerular filtration. Approximately 80-90% of a dose is recovered in urine as gabapentin, with the remainder as metabolites and minor amounts (≤1%) in feces. Biliary excretion is negligible.
Renal: 70% unchanged; biliary/fecal: 25%; metabolic: 5%
Category A/B
Category C
Anticonvulsant
Anticonvulsant